A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Recruiting now · Phase 1/Phase 2
Conditions studied: Melanoma
In brief
This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma
Key facts
- Study ID
- NCT06727630
- Run by
- Zhuhai Yufan Biotechnologies Co., Ltd
- People needed
- 40
- Starts
- 2024-03-14
- Expected to finish
- 2025-10-30
- Last updated by the study team
- 2024-12-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.